NeOnc Technologies Holdings Inc NTHI
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2025-03-26 |
| Shares Out. | 25,930,000 |
| Website | neonc.com ↗ |
| Phone | 18185706844 |
| Employees | 5 |
| Net Income | -$8.8M |
| Free Cash Flow | -$22.2M |
| Total Assets | $3.3M |
| Total Liabilities | $16.6M |
| Equity | -$13.2M |
About NeOnc Technologies Holdings Inc
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
NeOnc Technologies Holdings Inc is a publicly traded company under the ticker symbol NTHI on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
9 analysts (2026-07-01)